Acadia pulls plug on pimavanserin for adjunctive MDD
US regulators have, however, accepted the drug for review to treat hallucinations and delusions associated with dementia-related psychosis
Read More
Tag: CLARITY
New analysis backs benefit-risk profile of Merck’s Mavenclad
Merck has released new data showing a positive benefit-risk profile for its multiple sclerosis drug Mavenclad.
Read More
Merck’s MS pill Mavenclad launched in the UK and Ireland
Merck’s Mavenclad is now available in the UK and Ireland to treat highly active relapsing multiple sclerosis in adults.
Read More
EU nod for Merck’s MS therapy Mavenclad
Merck’s Mavenclad has bagged approval in the European Union, Norway, Liechtenstein and Iceland to treat highly active relapsing multiple sclerosis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
